Yıl: 2022 Cilt: 11 Sayı: 3 Sayfa Aralığı: 1153 - 1157 Metin Dili: İngilizce DOI: 10.5455/medscience.2022.05.108 İndeks Tarihi: 12-10-2022

Screening of ERBB4 SNP rs1026882 in a group of Schizophrenia patients and controls

Öz:
Schizophrenia is a multifactorial psychiatric disorder which is affected by genetic, environmental, and several other factors. ERBB4 is a gene with polymorphic sites which reported to be associated with schizophrenia. In this prospective study, we have tested the association of schizophrenia with one of the single nucleotide polymorphisms (SNP) called rs1026882 in the ERBB4 gene. We have screened the genotypes of rs1026882 in a case group consisted of 96 schizophrenia patients and 100 healthy controls. All samples were collected from the population living in Malatya-Turkey. First, we compared the distributions of SNP genotypes and alleles between the case and control groups, then between the subgroups of patients defined according to SAPS and SANS parameters and phenotypical outcomes of the disease. Even though there was no significant difference between the case and control groups, comparing the subgroups of patients revealed that, the CC genotype was more common than the CT through the patients showing avolition-apathy symptom (one of the parameters in SANS). In addition, TT genotype was significantly more frequent in the subgroup of patients exhibiting the phenotype of suicidal thoughts.Our study was limited with a relatively small sample size and a population living in a small geographical region. Therefore, screening of rs1026882 genotypes in larger case-control groups from different populations is thought to help to reveal stronger evidence for presence of the association between this SNP and schizophrenia phenotypes. As conclusion, we did not find a direct association between rs1026882 genotype and schizophrenia in general, but the TT genotype was associated with the phenotype of suicidal thoughts, and the CC genotype seems related to avolition-apathy symptom in our sample.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • Liddle P, Carpenter WT, Crow T. Syndromes of schizophrenia. Classic literature. Br J Psychiatry. 1994;165:721-7.
  • Escudero I, Johnstone M. Genetics of schizophrenia. Curr Psychiatry Rep. 2014;16:502-10.
  • Owen MJ, Craddock N, O’Donovan MC. Schizophrenia: genes at last? Trends Genet. 2005;21;518–25.
  • Rodriguez-Murillo L, Gogos JA, Karayiorgou M. The genetic architecture of schizophrenia: new mutations and emerging paradigms. Annu Rev Med. 2012;63:63–80.
  • Mostaid MS, Mancuso SG, Liu C, et al. Meta-analysis reveals associations between genetic variation in the 5' and 3' regions of Neuregulin-1 and schizophrenia. Transl Psychiatry. 2017;17:7:e1004.
  • Acar C, Sözen MM, Gözükara H, et al. Lack of association between catechol-Omethyltransferase and schizophrenia in a Turkish population. Turk J Biochemistry. 2015;40:205-9.
  • Sözen MM, Kartalcı Ş. Screening of three ERBB4 gene polymorphisms in a group of Turkish schizophrenia patients and controls. Turk J Biochemistry. 2015;40:463-71.
  • Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry. 2005;10:40-68.
  • Stefansson H, Sigurdsson E, Steinthorsdottir V, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet. 2002;71:877–92.
  • Stefansson H, Sarginson J, Kong A, et al. Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. Am J Hum Genet. 2003;72:83–7.
  • Williams NM, Preece A, Spurlock G, et al. Support for genetic variation in neuregulin 1 and susceptibility to schizophrenia. Mol Psychiatry. 2003;8:485–7.
  • Plowman GD, Green JM, Culouscou JM, et al. Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. Nature. 1993;366:473–5.
  • Junttila TT, Sundvall M, Määttä JA, et al. Erbb4 and its isoforms: selective regulation of growth factor responses by naturally occurring receptor variants. Trends Cardiovasc Med. 2000;10:304-10.
  • Lu CL, Wang YC, Chen JY, et al. Support for the involvement of the ERBB4 gene in schizophrenia: a genetic association analysis. Neurosci. Lett. 2010;481:120-5.
  • Corfas G, Roy K, Buxbaum JD. Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia. Nat Neurosci. 2004;7:575-80.
  • Silberberg G, Darvasi A, Pinkas-Kramarski R, Navon R. The involvement of ErbB4 with schizophrenia: association and expression studies. Am J Med Genet B Neuropsychiatr Genet. 2006;141B:142-8.
  • Nicodemus KK, Luna A, Vakkalanka R, Goldberg T, Egan M, et al. Further evidence for association between ErbB4 and schizophrenia and influence on cognitive intermediate phenotypes in healthy controls. Mol Psychiatry. 2006;11:1062-5.
  • Nicodemus KK, Law AJ, Radulescu E, et. al. Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls. Arch Gen Psychiatry. 2010;67:991-1001.
  • American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.) 2013. https://doi-org.ezproxy.frederick. edu/10.1176/appi.books.9780890425596
  • Andreasen NC, Olsen S. Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiatry. 1982;39:789-94.
  • Erkoç Ş, Arkonaç O, Atakli C, Özmen E. Negatif semptomlari değerlendirme ölçeğinin güvenilirliği ve geçerliliği. Düşünen Adam. 1991:14-15.
  • Kirkpatrick RW, Buchanan PD, McKenney LD, et al. The Schedule for the Deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res. 1989;30:119-23.
  • Faul F, Erdfelder E, Lang AG, Buchner A: G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;9:175–91.
  • Lu CL, Wang YC, Chen JY, et al. Support for the involvement of the ERBB4 gene in schizophrenia: a genetic association analysis. Neurosci Lett. 2010;481:120–5.
  • Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primer. 2015;12:15067.
APA Topaktaş Yıldırım Ö, KARTALCI Ş, SOZEN M (2022). Screening of ERBB4 SNP rs1026882 in a group of Schizophrenia patients and controls. , 1153 - 1157. 10.5455/medscience.2022.05.108
Chicago Topaktaş Yıldırım Özgü,KARTALCI ŞÜKRÜ,SOZEN MUSTAFA MERT Screening of ERBB4 SNP rs1026882 in a group of Schizophrenia patients and controls. (2022): 1153 - 1157. 10.5455/medscience.2022.05.108
MLA Topaktaş Yıldırım Özgü,KARTALCI ŞÜKRÜ,SOZEN MUSTAFA MERT Screening of ERBB4 SNP rs1026882 in a group of Schizophrenia patients and controls. , 2022, ss.1153 - 1157. 10.5455/medscience.2022.05.108
AMA Topaktaş Yıldırım Ö,KARTALCI Ş,SOZEN M Screening of ERBB4 SNP rs1026882 in a group of Schizophrenia patients and controls. . 2022; 1153 - 1157. 10.5455/medscience.2022.05.108
Vancouver Topaktaş Yıldırım Ö,KARTALCI Ş,SOZEN M Screening of ERBB4 SNP rs1026882 in a group of Schizophrenia patients and controls. . 2022; 1153 - 1157. 10.5455/medscience.2022.05.108
IEEE Topaktaş Yıldırım Ö,KARTALCI Ş,SOZEN M "Screening of ERBB4 SNP rs1026882 in a group of Schizophrenia patients and controls." , ss.1153 - 1157, 2022. 10.5455/medscience.2022.05.108
ISNAD Topaktaş Yıldırım, Özgü vd. "Screening of ERBB4 SNP rs1026882 in a group of Schizophrenia patients and controls". (2022), 1153-1157. https://doi.org/10.5455/medscience.2022.05.108
APA Topaktaş Yıldırım Ö, KARTALCI Ş, SOZEN M (2022). Screening of ERBB4 SNP rs1026882 in a group of Schizophrenia patients and controls. Medicine Science, 11(3), 1153 - 1157. 10.5455/medscience.2022.05.108
Chicago Topaktaş Yıldırım Özgü,KARTALCI ŞÜKRÜ,SOZEN MUSTAFA MERT Screening of ERBB4 SNP rs1026882 in a group of Schizophrenia patients and controls. Medicine Science 11, no.3 (2022): 1153 - 1157. 10.5455/medscience.2022.05.108
MLA Topaktaş Yıldırım Özgü,KARTALCI ŞÜKRÜ,SOZEN MUSTAFA MERT Screening of ERBB4 SNP rs1026882 in a group of Schizophrenia patients and controls. Medicine Science, vol.11, no.3, 2022, ss.1153 - 1157. 10.5455/medscience.2022.05.108
AMA Topaktaş Yıldırım Ö,KARTALCI Ş,SOZEN M Screening of ERBB4 SNP rs1026882 in a group of Schizophrenia patients and controls. Medicine Science. 2022; 11(3): 1153 - 1157. 10.5455/medscience.2022.05.108
Vancouver Topaktaş Yıldırım Ö,KARTALCI Ş,SOZEN M Screening of ERBB4 SNP rs1026882 in a group of Schizophrenia patients and controls. Medicine Science. 2022; 11(3): 1153 - 1157. 10.5455/medscience.2022.05.108
IEEE Topaktaş Yıldırım Ö,KARTALCI Ş,SOZEN M "Screening of ERBB4 SNP rs1026882 in a group of Schizophrenia patients and controls." Medicine Science, 11, ss.1153 - 1157, 2022. 10.5455/medscience.2022.05.108
ISNAD Topaktaş Yıldırım, Özgü vd. "Screening of ERBB4 SNP rs1026882 in a group of Schizophrenia patients and controls". Medicine Science 11/3 (2022), 1153-1157. https://doi.org/10.5455/medscience.2022.05.108